公开(公告)号：US20240094223A1

公开(公告)日：2024-03-21

申请号：US18502243

申请日：2023-11-06

Applicant: BIO-RAD EUROPE GMBH ,  BIO-RAD LABORATORIES, INC.

Inventor： ISABELLE BATXELLI-MOLINA ,  FLORIAN SALIPANTE ,  ROGER P. WALKER ,  JOHN FLANAGAN ,  JEANNETTE FAREH-MICHIEL

IPC: G01N33/68 ,  G16B25/10

CPC classification number: G01N33/6893 ,  G01N33/6869 ,  G16B25/10 ,  G01N2333/521 ,  G01N2333/5421 ,  G01N2333/575 ,  G01N2400/40 ,  G01N2800/085

Abstract: The invention provides a method of diagnosing Non-Alcoholic Steatohepatitis (NASH) and/or the hepatic fibrosis status of a subject, especially a subject afflicted with Non-alcoholic fatty liver disease (NAFLD) or NASH, based on the level of only three or more particular biomarkers. The invention further provides a kit suitable for performing said method and the use of said method and methods of treating patients diagnosed in accordance with the disclosed methods.

公开(公告)号：US20240053326A1

公开(公告)日：2024-02-15

申请号：US18230872

申请日：2023-08-07

Applicant: BROWN UNIVERSITY

Inventor： Wafik S. El-Deiry ,  Kelsey E. Huntington ,  Anna Louie

IPC: G01N33/50

CPC classification number: G01N33/5041 ,  G01N2800/52 ,  G01N2333/475 ,  G01N2333/521

Abstract: A method of treating a subject having colon cancer with a small molecule drug for treating colon cancer is described. The method includes determining the effect of the small molecule drug on the release of a plurality of immunomodulating factors by colon cancer cells; and treating the subject with a therapeutically effect amount of the drug if the effect of the drug on the release of immunomodulating factors indicates that the drug promotes anti-tumor immunity, or selecting a different drug for treating colon cancer if the effect of the drug on immunomodulating factor release indicates that the drug does not promote anti-tumor immunity. Methods of evaluating ongoing treatment using the method are also described.

公开(公告)号：US20240002493A1

公开(公告)日：2024-01-04

申请号：US18201599

申请日：2023-05-24

Applicant: Cognizance Biomarkers, LLC

Inventor： Todd WALLACH ,  Elisa A. WAXMAN ,  John GLEDHILL ,  Richard ST. CLAIR ,  Elizabeth BRAND

IPC: C07K16/24 ,  G16H10/40 ,  G16H10/60 ,  G16H50/70 ,  G16H50/20 ,  G16H20/10 ,  G01N33/68

CPC classification number: C07K16/244 ,  G16H10/40 ,  G16H10/60 ,  G16H50/70 ,  G16H50/20 ,  G01N2333/525 ,  G01N33/6896 ,  G01N2333/5446 ,  G01N2800/2857 ,  G01N2800/52 ,  G01N2333/521 ,  G16H20/10

Abstract: Epileptic seizures are difficult to diagnose and are often difficult to distinguish from several conditions with similar presentations, and therefore, diagnosis of seizures is often a long, expensive, and unreliable process. This invention provides biomarkers for identifying seizures and epilepsy, assays for measuring and assessing biomarker concentration, predictive models based on biomarkers and computational systems for detecting, assessing and diagnosing phasic and tonic changes associated with seizures and epilepsy in all clinical and healthcare settings. Diagnostic and treatment methods, systems, kits, and predictive models provided herein, provide quantitative and/or qualitative assessment in order to allow patients to proceed immediately to diagnostic and/or treatment protocols, and assess therapeutic treatment effectiveness.

公开(公告)号：US20230406917A1

公开(公告)日：2023-12-21

申请号：US18242199

申请日：2023-09-05

Applicant: MPO, INC.

Inventor： Kazuhiro KAWAMURA ,  Yuta KAWAGOE

IPC: C07K16/24 ,  C07K16/28 ,  C12N5/073 ,  G01N33/68

CPC classification number: C07K16/24 ,  C07K16/2866 ,  C12N5/0604 ,  G01N33/6863 ,  G01N33/689 ,  C12N2501/998 ,  G01N2333/521 ,  G01N2800/36 ,  G01N2800/7042

Abstract: Object of the present invention is to provide means for improving the quality of preimplantation embryos deteriorated with age or the like. The present invention relates to an agent for improving the quality of an egg, a fertilized egg, and/or an embryo, including a substance that inhibits signal transmission from CXCL5.

公开(公告)号：US20180246113A1

公开(公告)日：2018-08-30

申请号：US15547304

申请日：2016-02-05

Applicant: BRISTOL-MYERS SQUIBB COMPANY ,  Providence Health & Services

Inventor： Keith Sadoon BAHJAT ,  Helena Maria HOEN ,  Yoshinobu KOGUCHI ,  Alan J. KORMAN

IPC: G01N33/574 ,  C07K16/28 ,  C07K16/30 ,  A61K39/395 ,  A61K45/06

CPC classification number: G01N33/57492 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/55 ,  C07K16/2818 ,  C07K16/30 ,  C07K2317/21 ,  C07K2317/76 ,  G01N33/5743 ,  G01N33/57488 ,  G01N2333/521 ,  G01N2333/70539 ,  G01N2800/52

Abstract: Provided herein are methods for selecting a cancer patient for anti-CTLA-4 immunotherapy, or predicting whether a cancer patient will respond to anti-CTLA4 immunotherapy, based on measured levels of CXCL1 1 and/or sMICA. Such methods are useful for determining whether an anti-CTLA-4 immunotherapy is likely to improve overall survival of a cancer patient. Also provided herein are methods of treating a cancer patient with an anti-CTLA-4 immunotherapy, wherein the patient is first tested for levels of CXCL1 1 and/or sMICA. Also provided are methods for treating a cancer patient with a CXCL1 1 antagonist or sMICA ant agonist alone, or in combination with each other and/or with additional anti-cancer agents, such as a CTLA-4 antagonist.

公开(公告)号：US20180015093A1

公开(公告)日：2018-01-18

申请号：US15581414

申请日：2017-04-28

Applicant: Infinity Pharmaceuticals, Inc.

Inventor： Howard M. Stern ,  Jeffrey L. Kutok

IPC: A61K31/52 ,  A61K31/519 ,  A61K31/704 ,  A61K45/06 ,  C07D401/12 ,  C07D473/00 ,  C07D473/34 ,  G01N33/574 ,  A61K31/505 ,  G01N15/10 ,  G01N33/50 ,  C07D471/04 ,  G01N15/00

CPC classification number: A61K31/52 ,  A61K31/505 ,  A61K31/519 ,  A61K31/704 ,  A61K45/06 ,  C07D401/12 ,  C07D471/04 ,  C07D473/00 ,  C07D473/34 ,  G01N33/5011 ,  G01N33/574 ,  G01N2333/521 ,  G01N2333/525 ,  G01N2333/53 ,  G01N2333/5434 ,  G01N2333/9121 ,  G01N2333/96494 ,  A61K2300/00

Abstract: Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating cancers or hematologic disorders.

公开(公告)号：US09850286B2

公开(公告)日：2017-12-26

申请号：US14498317

申请日：2014-09-26

Applicant: LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE

Inventor： Ursula Gompels ,  David Dewin ,  Julie Catusse

IPC: C07K14/52 ,  C12N5/10 ,  C12N15/63 ,  C07K14/005 ,  A61K39/245 ,  C12N7/00 ,  A61K38/00 ,  A61K39/00

CPC classification number: C07K14/005 ,  A61K38/00 ,  A61K39/245 ,  A61K2039/53 ,  C07K14/523 ,  C12N7/00 ,  C12N2710/16034 ,  G01N2333/521 ,  G01N2500/00

Abstract: A novel cytokine, U83A, is described, as are variant forms of the cytokine, having a wide range of agonistic and antagonistic activity against chemokine receptors. Uses of the chemokine in treatment of a range of diseases, including cancers and HIV/AIDS, are described.

公开(公告)号：US09797910B2

公开(公告)日：2017-10-24

申请号：US14888982

申请日：2014-06-13

Applicant: Merck Sharp & Dohme Corp.

Inventor： Weixun Wang ,  Bernard Karsten Choi ,  Lucinda H. Cohen

IPC: G01N33/53 ,  G01N33/68

CPC classification number: G01N33/6863 ,  G01N33/6848 ,  G01N2333/521 ,  G01N2560/00

Abstract: The present invention relates to an assay for determining endogenous levels of analyte in vivo. In particular, the present invention is directed to an assay for determining endogenous levels of stromal cell-derived factor (SDF-1) isoforms in vivo.

公开(公告)号：US20170145089A1

公开(公告)日：2017-05-25

申请号：US15320106

申请日：2015-06-26

Applicant: SANOFI

Inventor： Corrine ESPERET ,  Alexandre JAGERSCHMIET ,  Christina SOUBRANE ,  Arun SUBRAMANIAM

IPC: C07K16/24 ,  C07K14/52 ,  G01N33/68 ,  C07K16/46

CPC classification number: C07K16/247 ,  A61K39/02 ,  A61K39/395 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K14/521 ,  C07K16/244 ,  C07K16/468 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/92 ,  C07K2317/94 ,  G01N33/6893 ,  G01N2333/521 ,  G01N2800/52

Abstract: Disclosed herein are safe doses of dual-V-region antibody-like binding proteins or fragments thereof, as well as methods for assessing binding of dual-V-region antibody-like proteins or fragments thereof to their targets, and methods of treating idiopathic pulmonary fibrosis (IPF) by administering safe doses of dual-V-region antibody-like binding proteins or fragments thereof. In some embodiments, the dual-V-region antibody-like binding proteins or fragments thereof bind both IL-4 and IL-13.

公开(公告)号：US20170088897A1

公开(公告)日：2017-03-30

申请号：US15315908

申请日：2015-05-29

Applicant: Npvartos AG

Inventor： Marianna ROWLANDS ,  Clemence Anne Jeanne Marie TESSIER ,  Paul Andrew WHITTAKER

IPC: C12Q1/68 ,  G01N33/68

CPC classification number: C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/6863 ,  G01N33/6884 ,  G01N2333/521 ,  G01N2800/12 ,  G01N2800/321 ,  G01N2800/52

Abstract: Pulmonary hypertension is a progressive disease of various origins that is associated with vascular remodelling and results in right heart dysfunction. Accumulating evidence indicates important roles of immune cells and inflammatory chemokines in the pathogenesis and progression of pulmonary hypertension. We have identified CCL21 as anti-remodelling efficacy biomarker for pulmonary hypertension. CCL21 was found to be highly sensitive and specific in discriminating pulmonary hypertension patients from matched controls. CCL21 was upregulated in pulmonary hypertension and down-regulated with treatment with an anti-remodelling agent.